NewLink Genetics Corp. (NASDAQ:NLNK) shares shot up 2.2% during mid-day trading on Friday . The stock traded as high as $11.00 and last traded at $10.92, with a volume of 81,208 shares trading hands. The stock had previously closed at $10.69.

Several brokerages have recently issued reports on NLNK. Zacks Investment Research raised shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 5th. Cantor Fitzgerald reissued a “buy” rating and set a $62.00 price objective on shares of NewLink Genetics Corp. in a research note on Friday, April 29th. Stifel Nicolaus reduced their price objective on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Robert W. Baird reissued a “buy” rating on shares of NewLink Genetics Corp. in a research note on Monday, May 16th. Finally, Jefferies Group reissued a “hold” rating and set a $10.00 price objective on shares of NewLink Genetics Corp. in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.29.

The firm’s 50-day moving average price is $11.19 and its 200 day moving average price is $17.96. The company’s market cap is $316.89 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, April 29th. The company reported ($0.82) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.70) by $0.88. The business had revenue of $4.34 million for the quarter, compared to analyst estimates of $2.08 million. On average, equities research analysts expect that NewLink Genetics Corp. will post ($2.83) EPS for the current year.

Other hedge funds and institutional investors have modified their holdings of the company. Russell Frank Co increased its position in shares of NewLink Genetics Corp. by 57.1% in the fourth quarter. Russell Frank Co now owns 265,422 shares of the company’s stock valued at $9,712,000 after buying an additional 96,512 shares during the last quarter. EQIS Capital Management increased its position in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in shares of NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares during the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.